Understand the source comparison
Mazdutide's Dual-Receptor Mechanism vs Single-Pathway GLP-1 Agonists
Semaglutide (Wegovy, Ozempic) and liraglutide (Saxenda, Victoza) work exclusively through GLP-1 receptor agonism. Binding to receptors in the hypothalamus to reduce appetite signaling and in the gut to slow gastric emptying. The appetite suppression is profoun
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Semaglutide (Wegovy, Ozempic) and liraglutide (Saxenda, Victoza) work exclusively through GLP-1 receptor agonism. Binding to receptors in the hypothalamus to reduce appetite signaling and in the gut to slow gastric emptying. The appetite suppression is profound, but the metabolic effect stops there. When caloric intake drops, the body compensates by reducing non-exercise activity thermogenesis (NEAT) by 200–400 calories daily and downregulating thyroid hormone conversion (T4 to T3), which limits fat oxidation even in a deficit. Semaglutide doesn't counteract this adaptation. It just makes eating less feel easier.
- Mazdutide adds glucagon receptor activation on top of GLP-1 signaling. Glucagon normally signals the liver to release stored glucose during fasting, but when combined with GLP-1 receptor activation, it shifts hepatic metabolism toward lipid oxidation instead of glycogenolysis. The result: increased hepatic fat burning, elevated thermogenesis, and reduced liver fat content independent of caloric restriction. A 2024 Phase 2 trial in obese adults (BMI 30–45) showed mazdutide 6mg weekly reduced liver fat by 58% at 24 weeks. Semaglutide 2.4mg achieved 35% reduction in comparable populations.
- The dual mechanism also prevents the glucose-lowering overcorrection that pure glucagon agonists cause. GLP-1 receptor activation blunts glucagon's hyperglycemic effect while preserving its thermogenic and lipolytic actions. This is why mazdutide improves insulin sensitivity (HOMA-IR reductions of 45–52% in trials) without hypoglycemia risk, even in non-diabetic subjects. Single-pathway peptides like semaglutide improve insulin sensitivity secondarily through weight loss. Mazdutide does it directly through receptor-level metabolic shifts.